BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31879047)

  • 1. Dihydroartemisinin inhibits the growth and invasion of gastric cancer cells by regulating cyclin D1-CDK4-Rb signaling.
    Fan HN; Zhu MY; Peng SQ; Zhu JS; Zhang J; Qu GQ
    Pathol Res Pract; 2020 Feb; 216(2):152795. PubMed ID: 31879047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways.
    Liang R; Chen W; Chen XY; Fan HN; Zhang J; Zhu JS
    Pathol Res Pract; 2021 Feb; 218():153318. PubMed ID: 33370709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
    Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
    J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cancer activity of DHA on gastric cancer--an in vitro and in vivo study.
    Sun H; Meng X; Han J; Zhang Z; Wang B; Bai X; Zhang X
    Tumour Biol; 2013 Dec; 34(6):3791-800. PubMed ID: 23907579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.
    Jiang S; Zhao C; Yang X; Li X; Pan Q; Huang H; Wen X; Shan H; Li Q; Du Y; Zhao Y
    Int J Mol Med; 2016 Jul; 38(1):113-22. PubMed ID: 27247259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1.
    Yuan C; Zhu X; Han Y; Song C; Liu C; Lu S; Zhang M; Yu F; Peng Z; Zhou C
    J Exp Clin Cancer Res; 2016 Jan; 35():15. PubMed ID: 26791264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sanguinarine inhibits the tumorigenesis of gastric cancer by regulating the TOX/DNA-PKcs/ KU70/80 pathway.
    Fan HN; Chen W; Peng SQ; Chen XY; Zhang R; Liang R; Liu H; Zhu JS; Zhang J
    Pathol Res Pract; 2019 Nov; 215(11):152677. PubMed ID: 31591052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of IC53d promotes the proliferation of gastric cancer cells by activating the AKT/GSK3β/cyclin D1 signaling pathway.
    Lin JX; Xie XS; Weng XF; Qiu SL; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Li P; Huang CM; Zheng CH
    Oncol Rep; 2019 May; 41(5):2739-2752. PubMed ID: 30864700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1.
    Sun F; Li N; Tong X; Zeng J; He S; Gai T; Bai Y; Liu L; Lu K; Shen J; Han M; Lu C; Dai F
    Cell Cycle; 2019 Sep; 18(18):2293-2306. PubMed ID: 31322047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
    Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
    Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
    Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
    J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo.
    Chen H; Sun B; Pan S; Jiang H; Sun X
    Anticancer Drugs; 2009 Feb; 20(2):131-40. PubMed ID: 19209030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy.
    Shimura T; Kakuda S; Ochiai Y; Kuwahara Y; Takai Y; Fukumoto M
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):540-8. PubMed ID: 21398050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3β/cyclin D1 pathway.
    Wang J; Li XM; Bai Z; Chi BX; Wei Y; Chen X
    J Ethnopharmacol; 2018 Jan; 210():1-9. PubMed ID: 28684297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.
    Tin AS; Sundar SN; Tran KQ; Park AH; Poindexter KM; Firestone GL
    Anticancer Drugs; 2012 Apr; 23(4):370-9. PubMed ID: 22185819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor of activated T cells c1 mediates p21-activated kinase 1 activation in the modulation of chemokine-induced human aortic smooth muscle cell F-actin stress fiber formation, migration, and proliferation and injury-induced vascular wall remodeling.
    Kundumani-Sridharan V; Singh NK; Kumar S; Gadepalli R; Rao GN
    J Biol Chem; 2013 Jul; 288(30):22150-62. PubMed ID: 23737530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via downregulating CIZ1 expression associated with TGF-β1 signaling.
    Li Y; Zhou X; Liu J; Gao N; Yang R; Wang Q; Ji J; Ma L; He Q
    Life Sci; 2020 May; 248():117454. PubMed ID: 32088211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin induces G
    Chen MJ; Cheng AC; Lee MF; Hsu YC
    J Cell Physiol; 2018 Jun; 233(6):4618-4625. PubMed ID: 28833099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.